by David Kent | May 28, 2013
. A few weeks ago, Italian private company Stamina came under considerable pressure regarding their controversial use of mesenchymal stem cells in patients. The Italian government, it seems, had authorized an unproven stem cell therapy for use in patients. The...
by Stacey Johnson | Apr 19, 2013
. In this podcast titled “Opportunities and Challenges in Developing Innovative Stem Cell Therapies,” Dr. Armand Keating focuses specifically on the commercialization of mesenchymal stem cells (stromal cells). He has established the largest stem cell transplant...
by Paul Krzyzanowski | May 22, 2012
Many readers may already have heard of Health Canada’s approval of Osiris’ Prochymal, a mesenchymal stem cell treatment for severe cases of pediatric Graft versus Host Disease (GvHD), with plenty of coverage circulating around the web. GvHD is a disease where...
by Stem Cell Network | Jan 27, 2011
Earlier this week, many of the world’s leading scientists engaged in developing stem cell-based treatments for Amyotrophic Lateral Sclerosis (ALS) or Motor Neuron Disease (MND) met for the first time as a group to share their work. Held in New York, the meeting was...
by Allison Van Winkle | Oct 8, 2010
High-throughput screening, in which many cell culture conditions can be tested using a combination of robotics, control software, and/or highly sensitive detection, allows researchers to explore new ideas quickly; thousands of combinations can be efficiently tested...
Comments